Showing papers in "Neurotherapeutics in 2019"

TL;DR: This review summarizes recent advancements in understanding of the potential use of Ginkgo biloba extract in the prevention of AD including its antioxidant property.

TL;DR: Development of intelligent aDBS, with an ability to deliver highly personalized treatment regimens and to create symptom-specific therapeutic strategies in real-time, could allow for significant further improvements in the quality of life for movement disorders patients with DBS that ultimately could outperform traditional drug treatment.

TL;DR: Urolithin A may exert neuroprotective effects and may aid in preventing d-gal-induced brain aging through activation of the miR-34a-mediated SIRT1/mTOR signaling pathway.

TL;DR: It is demonstrated that FMD can be a new means of preventing and treating PD through promoting a favorable gut microbiota composition and metabolites and increased dopamine levels in the recipient PD mice, suggesting that gut microbiota contributed to the neuroprotection of FMD for PD.

TL;DR: The proposed TIP algorithm can be used to automatically clean-up noisy fibers in deterministic tractography, with a potential to confirm the existence of a fiber connection in basic neuroanatomical studies or clinical neurosurgical planning.

TL;DR: Focused ultrasound boasts a number of key features such as multimodal compatibility, submillimeter steerable focusing, multifocal, high temporal resolution, coregistration, and the ability to monitor delivered therapy and temperatures in real time.

TL;DR: This work provides a review on the genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias and suggests promising therapeutic targets to potentially slow disease progression.

TL;DR: Interventional MRI-guided convection-enhanced delivery (iMRI-CED) is the gold standard for verifying accurate vector delivery in real time, and the availability of this advanced neurosurgical technique may accelerate the translation of the promising preclinical therapeutics under development for neurodegenerative disorders.

TL;DR: The evidence on the effects of exercise interventions on various mechanisms believed to support cognitive improvements: cerebral perfusion, synaptic neuroplasticity, brain volume and connectivity, neurogenesis, and regulation of trophic factors is summarized.

TL;DR: The concept of “directional deep brain stimulation” is summarized with its opportunities and challenges and the available study data and the use of imaging techniques to assist programming deep brain stimulating devices is discussed.

TL;DR: This review discusses and outlines the current state-of-the-art for speech BCI and explores what aspeech BCI using chronic ECoG might entail and what the challenges for the translation of speech BCIs to clinical populations remain.

TL;DR: The state of the art of cortical visual prosthesis is focused on by briefly explaining the design of current devices that are either under development or in the clinical testing phase and shed light on the challenges of each design.

TL;DR: Delivery of IL-13 enhances microglial/macrophage anti-inflammatory responses in vivo and in vitro, decreases ischemia-induced brain cell death, and improves sensory and motor functions in the pMCAo mouse model of cerebral ischemic stroke.

TL;DR: E2 treatment has been shown to ameliorate some of the behavioral and morphological changes seen in preclinical models of menopause; however, in clinical populations, the effects of E2 treatment on cognitive changes after menopausal transition are mixed.

TL;DR: An evidence-based solution for individualizing therapy that is driven by a bottom-up informatics approach is proposed for closed-loop brain stimulation for epilepsy.

TL;DR: The potential commonality of DNA damage repair pathways in HD and other neurodegenerative diseases is discussed, including nodes in the ataxia telangiectasia-mutated (ATM) complex, mismatch repair, and poly ADP-ribose polymerases (PARPs).

TL;DR: Therapeutic strategies targeting lysosomes and autophagic machinery have already been tested in several aging-related neurodegenerative diseases with promising results, suggesting that improving lysOSomal function could be similarly beneficial in preserving function in the aging brain.

TL;DR: More favorable response to quinidine in patients with KCNT1 variants distal to the NADP domain within the RCK2 domain may suggest a variant-specific response.

TL;DR: High-dose sodium selenate supplementation is well tolerated and can modulate CNS selenium concentration, although individual variation in selenum metabolism must be considered to optimize potential benefits in AD.

TL;DR: This review describes CYP46A1 in the context of cholesterol homeostasis in the brain and summarizes available experimental data on CYP 46A1 association with different neurologic diseases, including the mechanisms by which changes in the CYP47A1 activity in thebrain could be beneficial for these diseases.

TL;DR: Questions about which method (SEEG or SDEs) is superior for identification of the EZ and does it depend on the etiology of epilepsy?

TL;DR: Efavirenz treatment in the present work seems to represent a model of behavioral and other improvements independent of the levels of the amyloid peptides and provides insight into potential outcomes of the future clinical trial.

TL;DR: TBI causes a robust and persistent neuroinflammatory response that is associated with increased miR-155 expression in microglia/macrophages, andMiR- 155 inhibition reduces post-traumatic neuroinflammatory responses and improves neurological recovery, and may be a therapeutic target for TBI-related neuroinflammation.

TL;DR: The results are the first to show that pridopidine promotes functional neurorestoration in the damaged nigrostriatal system acting via the sigma-1 receptor.

TL;DR: The goal of this review is to examine the current understanding on metabolic dysfunction in AD, so that a potential target can be identified in the near future.

TL;DR: The disruption of protein homeostasis is proposed as the hub of SCA3 pathogenesis, being the molecular mechanisms and cellular pathways that are deregulated inSCA3 downstream consequences of the misfolding and aggregation of ATXN3.

TL;DR: A review of the mechanisms involved in repeat-mediated gene silencing and recent efforts aimed at development of therapeutics for Friedreich ataxia can be found in this article.

TL;DR: An overview of the advantages of HDFT in a neurosurgical context is provided, derived from considerable experience implementing the technique for academic and clinical purposes.

TL;DR: Various nucleic acid–based therapeutics for PD include strategies to deliver dopamine biosynthetic enzymes to boost dopamine production or modulate the basal ganglia circuitry in order to improve motor symptoms.

TL;DR: The evolution of FUS from the beginning in 1950s to current state-of-the-art is analyzed to provide an overall picture of actual and future applications of F US in oncology and cerebrovascular neurology reporting for each application the principal existing evidences.